Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

• New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure • There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering   from chronic heart failure• The studies build on results from the landmark EMPA-REG OUTCOME® trial
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news